The Abdominal Radiation Oncology Center is the most comprehensive facility of its kind in China and enjoys a high reputation both inside and outside the Zhejiang province. The Department of Abdominal Radiation oncologists provides research-driven, safe, accurate and high-quality patient care in collaboration with radiation physics, conducts research and technology development to advance treatment, and provides education on the clinical (physics) and technical aspects of radiation oncology. Our tools and expertise allow us to offer patients the most effective and advanced radiation treatments available, including new therapies that reduce or eliminate some of the side effects of radiotherapy.
Our department has complete radiotherapy equipment, including 8 linear accelerators, 1 Tomotherapy system (TOMO) and 2 CT simulators. In recent years, with the introduction of new technologies such as Volumetric Modulated Arc Therapy (VMAT), Stereotactic Body Radiation Therapy (SBRT), 4D-CT, Respiratory-gating, Image-Guided Radiation Therapy (IGRT), TOMO, the conformity and precision of radiotherapy has been improved, and the radiotherapy in some complicated cases have also been achieved. While improving the effectiveness of treatment, it can better protect the normal tissue and improve the quality of life of patients.
The department has 12 radiation oncologists, including 3 chief physicians, 3 associate chief physicians, and 25 nurses.
● Our oncologists focus on treating specific types of cancer, including gastrointestinal, hepatobiliary, pancreatic and other digestive system malignancies, lymphoma, malignancy of urinary system, malignancy of male genital system, malignancy of bone, soft tissue and skin.
● More than 1200 person-times of radiotherapy patients, more than 8000 person-times outpatients and 5000 person-times discharges annually.
● Our group adheres to the multidisciplinary diagnosis and treatment, and actively participate in the formation of multidisciplinary teams (MDT) of colorectal cancer, gastric cancer, lymphoma, urinary system, hepatobiliary, pancreatic tumors, and soft tissue tumors. Through our multidisciplinary approach, teams of experts review cases in daily meetings to ensure patients getting the best possible care.
● The Academic Leader Prof. Yuan Zhu and Prof. Luying Liu have participated in the development of many domestic guidelines and consensus on such as “Consensus of Chinese experts in perioperative treatment of resectable advanced colorectal cancer (2019)”, “Consensus and contouring atlas for the delineation of clinical target volume in radiotherapy for rectal cancer” in China, “Expert consensus on lymphoma diagnosis and treatment”, “Oral nutrition supplements consensus for cancer patients undergoing radiotherapy”, “Basic guidelines of quality control for radiotherapy”, etc.
● We have published over 50 peer-reviewed papers in prestigious domestic and international journals, including more than 20 SCI papers.
● We have been engaged in more than 20 multicenter phase II/III clinical trials domestically as participant membership, and initiated 2 investigator-led clinical research projects. Our center carried out neoadjuvant chemoradiotherapy for rectal cancer earlier in China. The long-term follow-up results showed that the pCR rate was 20%, the 10 years’ OS and DFS in the patients who received pCR was 90.9% and 90.9%, respectively. The OS and DFS in the ITT population at 10 years was 39.5% and 41.8%, respectively. In view of the above, pCR is an independent prognostic factor for locally advanced rectal cancer after preoperative chemoradiotherapy. In terms of perioperative treatment of rectal cancer, we participated in the “CinClare” study, a multicenter randomized phase III trial of capecitabine with or without irinotecan driven by UGT1A1 in neoadjuvant chemoradiation of locally advanced rectal cancer; the “STELLAR” study, 5Gy*5 short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer. We engaged in a series of national multicenter studies in terms of gastric cancer and lymphoma as well. Some results guide our current clinical practice. One result was reported on “BLOOD” in 2015 showed that radiotherapy alone and radiotherapy with or without chemotherapy were more effective than chemotherapy alone for extranodal nasal-type natural killer/T-cell lymphoma (NKTCL).
● We have carried out a series of new technology studies, including TOMO for total marrow radiotherapy before lymphoma bone marrow transplantation, and moderate-dose fractionated radiotherapy for prostate cancer patients, etc.
● On-going national multicenter clinical study
◆ Randomized controlled phase III clinical study of adjuvant chemoradiotherapy versus adjuvant chemotherapy for locally advanced AEG after abdominal standard D2 radical resection.
◆ A multicenter retrospective study of DLBCL molecular typing and radiotherapy in the era of modern chemotherapy.
◆ Clinical study of SBRT with S-1 versus conventionally fractionated radiotherapy with S-1 in the treatment of pancreatic cancer.
● On-going basic research
◆ Has-miR-4274 mediates PD-L1 expression in microsatellite stability colorectal cancer.
◆ The mechanism of hsa-miR-576-5p promoting EMT by regulating the classical Wnt pathway through targeted silence Wnt5a in colorectal cancer.
◆ Transformative study of screening peripheral blood molecular markers for early diagnosis of pancreatic cancer.
◆ Correlation and mechanism of hsa-miR-576-5p expression with the development of colorectal cancer.
● Evaluate the potential of current practices and devices through pre-clinical treatment planning and imaging studies.
● Collaborate with radiation oncologists in the conduct of national and international cooperative group trials.
● Advance the state of the art at our center and elsewhere through research, development, and translation of research into clinical practice.
●Conduct the annual national continuing medical education project “New technologies and specifications for radiotherapy for abdominal tumors”.
● Conduct the annual national continuing medical education project “Standard treatment of lymphoma”.
● Host “The first symposium on local treatment of metastatic colorectal cancer in Hangzhou”.
● Teach students in Clinical medicine undergraduate programs
● Mentor and guide the research of master fellows
● Teach and mentor students of the Graduate School of Biomedical Sciences (Medical Physics Program)
● Mentor and guide the clinical standardized training for radiation oncology residents
For more information on the abdominal radiotherapy department, phone: +86-0571-88128142, email: email@example.com.
Last Updated: Mar. 2020